Last reviewed · How we verify
bimatoprost 0.03% ophthalmic solution
Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.
Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | bimatoprost 0.03% ophthalmic solution |
|---|---|
| Also known as | LUMIGAN® 0.03%, LUMIGAN 0.3 mg/ml, Narrow band ultraviolet rays B, Fractional carbon dioxide laser, LUMIGAN® |
| Sponsor | Allergan |
| Drug class | Prostaglandin F analog |
| Target | Prostaglandin F receptor (FP receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Bimatoprost mimics the action of prostaglandin F by activating F-prostanoid receptors on the ciliary muscle bundle and trabecular meshwork. This activation enhances drainage of aqueous humor through the uveoscleral (unconventional) pathway, reducing intraocular pressure. The drug is applied topically as an ophthalmic solution, allowing direct local action in the anterior chamber of the eye.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Increased iris pigmentation (darkening)
- Conjunctival hyperemia (redness)
- Eyelash growth (hypertrichosis)
- Eye irritation or discomfort
- Periocular skin darkening
Key clinical trials
- Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma (PHASE4)
- Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Comparison of Different Drugs on Ocular Surface Disease in Glaucoma Patients: a Prospective Randomised Study
- Topical Bimatoprost for Chemical Blepharoplasty (EARLY_PHASE1)
- Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose (PHASE4)
- Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension (PHASE1, PHASE2)
- Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma (PHASE4)
- Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005% (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bimatoprost 0.03% ophthalmic solution CI brief — competitive landscape report
- bimatoprost 0.03% ophthalmic solution updates RSS · CI watch RSS
- Allergan portfolio CI